

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4925825

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HERRIOT TABUTEAU	03/13/2017
RECEIVING PARTY DATA	
Name:	ANTECIP BIOVENTURES II LLC
Street Address:	630 FIFTH AVENUE, SUITE 2000
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10111
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15897947
CORRESPONDENCE DATA	
Fax Number:	(435)252-1361
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	949-202-1900
Email:	Docket@mabr.com
Correspondent Name:	BRENT A. JOHNSON
Address Line 1:	20 PACIFICA, SUITE 1130
Address Line 4:	IRVINE, CALIFORNIA 92618
ATTORNEY DOCKET NUMBER:	A3226.10003US71
NAME OF SUBMITTER:	MARIA NADAL
SIGNATURE:	/Maria Nadal/
DATE SIGNED:	04/20/2018
Total Attachments: 9	
source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page1.tif	
source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page2.tif	
source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page3.tif	
source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page4.tif	
source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page5.tif	
source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page6.tif	

source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page7.tif

source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page8.tif

source=03-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page9.tif

ASSIGNMENT

THIS ASSIGNMENT is made by **Herriot Tabuteau** (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNOR") to **Antecip Bioventures II LLC**, a legal entity having its principal place of business at 630 Fifth Avenue, Suite 2000, New York, New York 10111 (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNEE").

WHEREAS, ASSIGNOR has invented and owns rights in, to and under new and useful inventions for which an application(s) for or Letters Patent has been filed as indicated on Exhibit A (hereafter "Inventions");

WHEREAS, ASSIGNOR believes himself to be the original and true inventor of the Inventions;

WHEREAS, ASSIGNEE desires to acquire the Inventions and improvements thereto;

AND WHEREAS, ASSIGNOR and ASSIGNEE desire to have a recordable instrument assigning ASSIGNEE as owners of the entire right, title and interest in, to, and under the Inventions and improvements thereto owned by ASSIGNOR;

NOW THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign, transfer, convey, endorse, and hereby set over unto ASSIGNEE the full and exclusive right, title and interest in, to and under the Inventions to be held and enjoyed by ASSIGNEE, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made including the full and exclusive right, title and interest in, to and under 1) any patent application, or any other legal instrument equivalent thereof, including, without limitation, continuation, division, continuation-in-part, substitute, reexamination, renewal, inventor's certificate, and utility model, which has been or may be submitted therefor and thereon anywhere in the World, such term defined herein as including the United States of America, its territorial possessions, and any and all foreign countries under national laws or under the provisions of the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international treaty equivalent thereof; 2) any Letters Patent, or any other legal instrument equivalent thereof, which has been or may be granted therefor and thereon, in the World, for the full term or terms for which the same may be granted; 3) any reissue, extension, or any other legal instrument equivalent thereof, on any patent application or Letters Patent which has been or may be granted therefor and thereon in the World; and 4) any right to claim priority to a filing date, or any other legal equivalent thereof, which has been or may be claimed by any patent application or Letters Patent therefor and thereon in the World.

ASSIGNOR hereby covenants and agrees to perform any lawful action when deemed essential by and to ASSIGNEE's full enjoyment, protection, enforcement and title in, to and under the Inventions and rights hereby transferred, including, but not limited to, promptly communicating and providing any and all known and accessible facts, data or any other pertinent information; promptly executing and delivering any and all papers, documents, forms, declarations, oaths, affidavits or any other legal instrument; promptly assisting and participating in any and all depositions, hearings, proceedings, trials, appeals, or any other legal procedure; promptly testifying under oath in any and all interference, post grant review, litigation or any other

administrative or judicial proceeding; and promptly completing any and all actions necessary or desirable to carry out any and all purposes thereof, relating to any and all proceedings in connection with the submission, procurement, issuance, maintenance, enforcement or defense of the inventions and rights hereby transferred.

A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.

IN TESTIMONY WHEREOF, I hereunder set my hand this 13th day of March, 2017.

ASSIGNOR

Herriot Tabuteau


Signature

State of CALIFORNIA)
)
County of ORANGE) ss.:

On this 13 day of March, 2017, before me, Maria Emilia Nadal, personally appeared **Herriot Tabuteau**, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

Notary Public



A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.

ACKNOWLEDGED AND CONFIRMED, I hereunder set my hand this 13th day of March, 2017, as a duly authorized representative of ASSIGNEE.

ASSIGNEE



Name: Herriot Tabuteau, MD
Title: Managing Member

State of CALIFORNIA)
County of ORANGE)

ss.:

On this 13 day of March, 2017, before me, Maria Emilia Nadal, personally appeared **Herriot Tabuteau** who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.


Notary Public




EXHIBIT A**Patent Rights: Patents and Patent Applications**

Title	Application/Serial No.	Filing Date
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/182/253	6/14/2016
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	15/182,378	6/14/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/188,725	6/21/2016
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/206,057	7/8/2016
THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	15/211,827	7/15/2016
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	15/213,283	7/18/2016
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	15/216,545	7/21/2016
OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS	15/217,752	7/22/2016
OSTEOCLAST INHIBITORS FOR BONE MARROW LESIONS	15/217,773	7/22/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	15/223,548	7/29/2016

BUPROPION AS A MODULATOR OF DRUG ACTIVITY	15/224,233	7/29/2016
METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	15/223,487	7/29/2016
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/236,290	8/12/2016
IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	15/238,614	8/16/2016
COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	15/238,182	8/16/2016
BISPHOSPHONATES INHIBIT PAIN, BONE LOSS AND INFLAMMATION OF COMPLEX REGIONAL PAIN SYNDROME	62/378,140	8/22/2016
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	15/246,325	8/24/2016
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/263,138	9/12/2016
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	15/269,799	9/19/2016
HYDROXYBUPROPION AND RELATED COMPOUNDS AS MODULATORS OF DRUG PLASMA LEVELS	15/275,177	9/23/2016
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/280,938	9/29/2016

OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	62/405,838	10/7/2016
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/335,381	10/26/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/347,696	11/9/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/348,842	11/10/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/348,808	11/10/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/349,926	11/11/2016
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	15/352,461	11/15/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/353,550	11/16/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/354,862	11/17/2016

COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/354,908	11/17/2016
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/356,434	11/18/2016
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	15/357,769	11/21/2016
CO-ADMINISTRATION OF STEROIDS AND ZOLEDRONIC ACID TO PREVENT AND TREAT PAIN	15/357,932	11/21/2016
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/360,886	11/23/2016
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/364,117	11/29/2016
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	15/365,748	11/30/2016
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/367,048	12/1/2016
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/368,355	12/2/2016
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/371,052	12/6/2016
NERIDRONIC ACID MOLECULAR COMPLEX FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	62/431,287	12/7/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/377,907	12/13/2016

COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/378,939	12/14/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/380,824	12/15/2016
CO-ADMINISTRATION OF STEROIDS AND ZOLEDRONIC ACID TO PREVENT AND TREAT PAIN	15/384,125	12/19/2016
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/385,415	12/20/2016
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	15/386,858	12/21/2016
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	15/403,073	1/10/2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	62/445,646	1/12/2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/408,783	1/18/2017
ADMINISTRATION OF ZOLEDRONIC ACID TO TREAT PAIN ASSOCIATED WITH ANKYLOSING SPONDYLITIS	15/414,402	1/24/2017

COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/416,995	1/26/2017
COMPOSITIONS COMPRISING DASATINIB FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/421,205	1/31/2017
COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	15/426,908	2/7/2017
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	15/432,777	2/14/2017
OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS	15/438,513	2/21/2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/439,774	2/22/2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/446,971	3/1/2017